Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05923008 |
| Title | A Phase 1/2 Clinical Study to Evaluate the Safety and Tolerability of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Innovent Biologics (Suzhou) Co. Ltd. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | AUS |